In a business combination achieved in stages, this element represents a narrative description of the history, developments, or effect of the acquisition relative to the percentage of equity in the acquiree held by the acquirer immediately before the acquisition date. Such description may describe any gain recognized as a result of the acquisition.

No definition available.

+ Details

Name:	us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeDescription
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

+ Details

Name:	us-gaap_CommonStockValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_BusinessAcquisitionAxis=spex_CBMBiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=spex_EscrowAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Recent Events (Details Narrative) - USD ($) $ in Thousands	Oct. 10, 2018	Sep. 30, 2018	Dec. 31, 2017
Common stock share issued		8,542,542	6,234,910
Common stock value (in dollars per share)		$ 1
CBM Biopharma Inc [Member] \| Subsequent Event [Member]
Common stock share issued	15,000,000
Common stock value (in dollars per share)	$ 1
CBM Biopharma Inc [Member] \| Subsequent Event [Member] \| Escrow Agreement [Member]
Description of merger consideration	<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font: 10pt Times New Roman, Times, Serif">the Company shall deposit with the Escrow Agent 1,500,000 shares from the Stockholder Merger Consideration otherwise deliverable to the stockholders of CBM who own beneficially and of record greater than 10% of the CBM common stock issued and outstanding immediately prior to the Closing.</font></p>